NEW YORK--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) will present at the Jefferies Healthcare Conference in New York City on Wednesday, June 27 at 9:40 AM/ET. Dr. Frank E. O’Donnell Jr., Accentia Biopharmaceutical’s Chairman and Chief Executive Officer, will update attendees on the Company’s ongoing Fast Tracked Phase 3 Clinical trial for SinuNase, which is in development to treat Chronic Sinusitis, BiovaxID, a Fast Tracked anti-cancer vaccine in Phase 3 clinical development for Non-Hodgkin’s Lymphoma, and Revimmune, a recently licensed therapeutic in development that the Company will enter into a Phase 3 clinical trial with a lead indication for Multiple Sclerosis.
